We are international
Donate
• advocacy   TEXT SIZE   
advocate of the month

Advocacy Update - September 2012
09.19.12
Header

Congratulations to our September Advocates of the Month!
This month we honor Sue Bouzounis, Kim Marrelli, Teresa O'Connor, Karen Vorhies and Shirley Belknap who all have done an amazing job collecting signed postcards for our Postcards for Parity Program. According to Kim,

Advocate Kim Marrelli

"Helping out with the Postcards for Parity Program was a no-brainer. This issue has the potential to affect all MM patients. To me, treating all cancer treatments equally is just common sense. When I explain the issue in these terms, people just naturally want to help." Read these Rockstars' tips for collecting postcards here.

ONLINE RESOURCES

Missed the Advocacy Webinar? Have no Fear; we've got it here. A lot of fun was had as we walked through the 10 Steps to Building a Relationship with your Legislator this Election Season. Watch it today!

meet your legislator image



Your Stories Make Legislation Happen
Over the years we have shared stories with legislators across the country of patients who have had trouble accessing their oral anticancer medication because of high out of pocket costs; like Kelly, Caethe and Robert. We have learned that nothing makes a bigger impact than putting a face on the situation that is placing a huge financial strain on many Americans. Now we want to hear YOUR story. In the upcoming year we will again be focused on passing legislation that encourages insurance companies to keep up with innovation. If you are a patient with private, commercial insurance and have high out-of-pocket expenses for your oral therapies, that may prevent you from filling your prescription, please contact us to share your stories. While we need folks from every state, Wisconsin and Tennessee are currently high priorities based on the legislative landscapes in those states. Please email your story to Aimee with your name, address and phone number.

Do you live in Atlanta or the surrounding areas?

This December we will be hosting our 3rd Annual Advocacy Training at ASH. We are excited to be on the ground with advocates from Georgia to build the base for a strong Georgian Action team. This year we will go over the basics of advocacy and discuss the current political landscape for cancer patients post the 2012 elections.

Register Today



First Oral Drug for Prostate Cancer has IMF making sure EVERY patient knows the Law in their home state.
Director of US Advocacy, Meghan Buzby, presented to 250 advocates from Zero-The Project to End Prostate Cancer on the work we are doing around the country on oral chemotherapy access legislation. We made sure the patients and caregivers who attended their DC summit were educated about the laws that have been passed in each state to enable them to get the new treatment without suffering unnecessary cost disparity. These advocates are now armed with our Oral Parity Legislation Fact Sheets to make sure their doctors are informed of the laws in their states. Have you brought your doctors and nurses a Fact Sheet yet? Click Here

Action alert

Take Action Today
by checking out our
Action Center

to see what is happening
in your state.


Advocacy Tip of the Month

** We know sometimes you just can't collect the postcard right after someone signs it. In these cases, before you give it to someone, put a stamp on the card to make it easy for people to just drop it in the mailbox.**

Not yet a member of the Myeloma Action Network? Click here to sign up!
tip star

 related videos
 related articles
#AskDrDurie: My Mai...
#AskDrDurie: Can Mye...
10 PASSI PER CURA MI...
10 Steps to Better C...
10 Steps to Happy Ho...
2011 IMF Holiday Gif...
New Study: The Searc...
Comprender El Tratam...
...
ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Oc...
Advocacy Update: The...
As the Bill Turns......
ASCO 2012: Dr. Pasho...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Pande...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Weise...
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken An...
Audio Recording of C...
August 2013 Advocate...
Breaking News: Pomal...
FDA Recognition of E...
Freelite and Hevylit...
Health Reform and Yo...
Highlights from the ...
IMF 6th Annual Comed...
IMF Board Member Edi...
IMF Nurse Leadership...
IMF Responds to Prop...
IMF TV
IMWG 2014 Conference...
Infoline
International Myelom...
It is Officially Mye...
jc test
Live from ASH 2012: ...
Live! The Boca Raton...
Living Well with Mye...
Living Well With Mye...
Myelom Merkur - Früh...
MYELOMA AWARENESS MO...
Myeloma Canada Annou...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Febr...
Myeloma Minute Janu...
Myeloma Minute July...
Myeloma Minute June...
Myeloma Minute Marc...
Myeloma Minute May ...
Myeloma Minute Nove...
Myeloma Minute Octo...
Myeloma Minute Octo...
Myeloma Minute Sept...
Myeloma MinuteJune 1...
Myeloma MinuteMay 24...
Myeloma Today Spring...
New! Free Teleconfer...
One Myeloma Nation
Patienten Handbuch
Pomalidomide + carfi...
Should Myeloma Patie...
Special Myeloma Minu...
STEP 7: CONSOLIDATIO...
STEP 8: KEEPING TRAC...
Stillwater, Minn., M...
Teleconference: Myel...
The Emerging Role of...
The Hope Society
THE IMF AT ASH 2012
The IMF Gains Nation...
The IMF Spearheads N...
The Importance of Cl...
The IMWG Conference ...
The International My...
The International My...
The International My...
View the IMF’s Multi...
Webcast from the 201...
Клиническое значение...

ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
#AskDrDurie: My Maintenance was Stopped Because the Side Effects were Too Bad. How Common is That?
#AskDrDurie: Can Myeloma Run In The Family?
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care®
10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique

New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage

Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre



Third in the popular series of debates that debuted in Amsterdam in 2012.

Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific

ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - October 2013
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken Anderson's Overview
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
August 2013 Advocate of the Month: Judy Lewis
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Freelite and Hevylite will help the Black Swan Research Initiative find the best treatment to cure multiple myeloma
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
Highlights from the 5th Annual IMWG Summit: Part 2
IMF 6th Annual Comedy Celebration
benefiting the Peter Boyle Research Fund
October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
IMF TV
IMWG 2014 Conference Series Debate: Making Sense of Treatment
Infoline
International Myeloma Foundation Expresses Disappointment at Oncologic Drugs Advisory Committee (ODAC) Recommendation Against New Myeloma Treatment Panobinostat
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Living Well With Myeloma:
Understanding the Immune System and Lab Values in Myeloma
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 24, 2013
Myeloma Minute
October 25, 2012
Myeloma Minute
September 18, 2014
Myeloma Minute
June 13, 2013
Myeloma Minute
May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
One Myeloma Nation
Patienten Handbuch
Pomalidomide + carfilzomib trial recruiting patients.
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Gains National Recognition for Myeloma Awareness Month in 2014
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie
September 8,2011
The IMWG Conference Series "Making Sense of Treatment"
June 11, 2014
The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®
The International Myeloma Foundation Reports Live from the 2013 ASH Meeting in New Orleans
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
View the IMF’s Multiple Myeloma Journalists’ Workshop and Webcast from ASH 2013 in New Orleans
Webcast from the 2014 Boca Raton Patient & Family Seminar
February 28 - March 1, 2014

Клиническое значение электрофореза белковых фракций